Compare TNET & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | OCS |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | Switzerland |
| Employees | 2700 | 60 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2000 | N/A |
| Metric | TNET | OCS |
|---|---|---|
| Price | $47.58 | $11.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $65.80 | $42.00 |
| AVG Volume (30 Days) | 360.2K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.57% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.90 | N/A |
| Revenue | ★ $5,010,000,000.00 | N/A |
| Revenue This Year | N/A | $466.06 |
| Revenue Next Year | $3.30 | $479.73 |
| P/E Ratio | $25.17 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.67 | $10.52 |
| 52 Week High | $77.61 | $34.48 |
| Indicator | TNET | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 63.42 | 22.63 |
| Support Level | $34.47 | N/A |
| Resistance Level | $49.50 | $21.82 |
| Average True Range (ATR) | 1.94 | 1.80 |
| MACD | 0.13 | -0.99 |
| Stochastic Oscillator | 78.87 | 3.27 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.